Ranbaxy Launches Avessa capsules for the Treatment of Asthma

Ranbaxy Laboratories Ltd on September 12 2006 has announced the launch of its branded product, Avessa (Formoterol + Fluticasone) inhalation capsules in India for the treatment of Asthma. This unique combination has been launched for the first time in the world combining the fastest acting Long Acting Beta 2 Agonist Formoterol and the most potent inhaled corticosteroid Fluticasone. Avessa is available as Rheocaps Avessa 100 mcg, Avessa 250 mcg, Avessa 500 mcg, depending on the severity of Asthma patients. The product is to be used only with the Rheohaler, which is the world's first capsule based multidose dry powder inhaler.

Commenting on the launch, Sanjeev I Dani, Regional Director, India & Middle East, of the Company, said, "We are delighted to launch the world's first unique combination product Avessa, in India, which reinforces our strong commitment to develop and introduce convenient solutions for asthmatic patients. The introduction of a series of new products in the field of asthma underscores our commitment to the physicians and patients in this segment.".

Earlier during the year, the Company had launched Osonide (Ciclesonide) Inhaler, a novel once-a-day, product in this segment. In May this year, the Company entered into an in-licensing agreement for the Indian domestic market, with the Netherlands based Pharma Company, Eurodrug Laboratories, for the asthma product Doxophylline - a Novel Xanthine Bronchodilator, sold under the brand name "Synasma".

India presently has an estimated 15-20 million asthmatic patients and the estimated prevalence rate in 5-11 year old children is between 10-15%. A large segment of population is susceptible to this disorder. The classified triggers for asthma include environment pollutants, molds, dust mites, certain food etc and the disease affects all sections of the society.

Source : Equity Bulls

Keywords